Systemic pilocarpine for treatment of xerostomia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 10, 2008, Pages 1333-1340

  Berk, Lawrence ^a  

^a TAMPA GENERAL HOSPITAL   (United States)

Author keywords

131I; Pilocarpine; Radiation therapy; Sj gren's syndrome; Xerostomia

Indexed keywords

CARBON 14; IODINE 131; PILOCARPINE; PLACEBO;

CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HUMAN; HYPERPARATHYROIDISM; IRRADIATION; LACRIMATION; NAUSEA; NONHUMAN; RADIATION CARCINOGENESIS; RADIATION DOSE; REVIEW; RHINITIS; SALIVATION; SIDE EFFECT; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SWEATING; SYSTEMIC THERAPY; THYROID CANCER; URINARY FREQUENCY; VASODILATATION; XEROSTOMIA;

ADMINISTRATION, ORAL; HEAD AND NECK NEOPLASMS; HUMANS; MUSCARINIC AGONISTS; PILOCARPINE; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALIVARY GLANDS; SJOGREN'S SYNDROME; THYROID NEOPLASMS; XEROSTOMIA;

EID: 55049138660     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.10.1333     Document Type: Review

References (44)

1. Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database Syst Rev 2007;18:CD003782
2. Gerrard AW. The alkaloid of jaborandi. Chem Druggist 1875;192
3. Langley JN. The action of jaborandi on the heart. J Anat Physiol 1875;(Pt 1):187-201
4. Marshall CR. On the physiological action of the alkaloids of jaborandi leaves. J Physiol 1904;31:120-56
5. Sandhu SS, Abreu IN, Colombo CA, Mazzafera P. Pilocarpine content and molecular diversity in jaborandi. Scientia Agricola 2006;63:478-82
6. Codding PW, James MNG. The structure of pilocarpine hydrochloride, C11H17N202+.cl-: a muscarinic alkaloid. Acta Crystallogr B 1984;40:429-34
7. Ishii M, Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharm Des 2006;12:3573-81
8. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000;97:9579-84
9. Nakamura T, Matsui M, Uchida K, et al. M3 muscarinic acetylcholine receptor plays critical role in parasympathetic control of salivation in mice. J Physiol Lond 2004;558(Pt 2):561-75
10. Omori Y, Endo T, Hara Y, et al. Absorption, distribution and excretion of 14C-pilocarpine following oral administration to rats. Arzneimittelforschung 2004;54(3):171-8
11. Omori Y, Asari T, Maruyama K, et al. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung 2003;53:342-50
12. Weaver ML, Tanzer JM, Kramer PA. Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. Pharm Res 1992;9:1064-9
13. Tanzer JM, Kramer PA, Schulman P, Willard AK. A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. J Dent Res 1995;74:1845-9
14. Aromdee C, Fawcett JP, Ferguson MM, Ledger R. Serum pilocarpine esterase activity and response to oral pilocarpine. Biochem Mol Med 1996;59:57-61
15. Wasnich R, Gallagher S, Stanek S, et al. Salivary flow rates and pharmacokinetics in healthy Japanese and Caucasian volunteers administered oral pilocarpine: a comparative study. Clin Drug Investig 2003;23:411-7
16. Salagen® tablets: MGI PHARMA. Available from: http://www.mgipharma.com/pdfs/salagen_pi.pdf [Accessed August 2008]
17. Fox PC, Atkinson JC, Macynski AA, et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991;151:1149-52
18. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5
19. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-31
20. Taweechaisupapong S, Pesee M, Aromdee C, et al. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J 2006;51:333-7
21. Schuller DE, Stevens P, Clausen KP, et al. Treatment of radiation side effects with oral pilocarpine. J Surg Oncol 1989;42(4):272-6
22. Hamlar DD, Schuller DE, Gahbauer RA, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996;106:972-6
23. Scarantino C, LeVeque F, Swann RS, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol 2006;4:252-8
24. Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 97-09. Int J Radiat Oncol Biol Phys 2003;56:832-6
25. Lent Soma scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995;31:1049-91
26. Burlage FR, Roesink JM, Kampinga HH, et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 2008;70:14-22
27. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007;19:83-6
28. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49:546-9
29. Rhodus NL, Schuh MJ. Effects of pilocarpine on salivary flow in patients with sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1991;72:545-9
30. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 study group. Arch Intern Med 1999;159:174-81
31. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in sjogren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol 2004;10:169-77
32. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, et al. Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2007;39:431-4
33. Jacobs CD, Van Der Pas M. A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Huntington, NY) 1996;10:16-20
34. Lee SK, Lee SW, Chung SC, et al. Analysis of residual saliva and minor salivary gland secretions in patients with dry mouth. Arch Oral Biol 2002;47:637-41
35. Dawes C, Odium O. Salivary status in patients treated for head and neck cancer. J Can Dent Assoc 2004;70:397-400
36. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704
37. Dawes C. How much saliva is enough for avoidance of xerostomia? Caries Res 2004;38:236-40
38. Rhodus NL. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with sjogrees syndrome. Oral Dis 1997;3:93-8
39. Pilocarpine. Available from: http://en.wikipedia.org/wiki/Pilocarpine [Accessed August 2008]
40. Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987;59:1123-5
41. Fuertes CS, Setoain PX, Rovirosa Casino A, et al. Utility of pilocarpine evaluated by salivary gland scintigraphy and salivary flow in the treatment of radiation-induced xerostomia in head and neck cancer patients. Rev Esp Med Nucl 2004;23:259-66
42. Gornitsky M, Shenouda G, Sultanem K, et al. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:45-52
43. Haddad P, Karimi M. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiother Oncol 2002;64:29-32
44. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine fbr the treatment of ocular symptoms in patients with sjogren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003;62:1204-7